CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $623,295 | -11.2% | 13,732 | +9.8% | 0.00% | -100.0% |
| Q2 2023 | $702,255 | +32.8% | 12,509 | +6.4% | 0.00% | – |
| Q1 2023 | $528,651 | +24.1% | 11,758 | +12.2% | 0.00% | – |
| Q4 2022 | $425,849 | -25.3% | 10,476 | +20.2% | 0.00% | -100.0% |
| Q3 2022 | $570,000 | -95.5% | 8,714 | -95.8% | 0.00% | -90.0% |
| Q2 2022 | $12,717,000 | -55.4% | 209,267 | -44.3% | 0.01% | -44.4% |
| Q4 2021 | $28,482,000 | -32.5% | 375,854 | -0.2% | 0.02% | -37.9% |
| Q3 2021 | $42,171,000 | -30.9% | 376,762 | -0.0% | 0.03% | -31.0% |
| Q2 2021 | $61,005,000 | +79.6% | 376,832 | +35.2% | 0.04% | +68.0% |
| Q1 2021 | $33,974,000 | -38.8% | 278,815 | -23.1% | 0.02% | -41.9% |
| Q4 2020 | $55,492,000 | -2.5% | 362,429 | -46.7% | 0.04% | -14.0% |
| Q3 2020 | $56,910,000 | +61.1% | 680,420 | +41.5% | 0.05% | +51.5% |
| Q2 2020 | $35,327,000 | +618.5% | 480,700 | +314.6% | 0.03% | +450.0% |
| Q1 2020 | $4,917,000 | – | 115,936 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |